211 related articles for article (PubMed ID: 9815532)
1. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.
Bajorin DF; Chapman PB; Wong G; Coit DG; Kunicka J; Dimaggio J; Cordon-Cardo C; Urmacher C; Dantes L; Templeton MA
Cancer Res; 1990 Dec; 50(23):7490-5. PubMed ID: 2253196
[TBL] [Abstract][Full Text] [Related]
3. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
4. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
[TBL] [Abstract][Full Text] [Related]
5. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
6. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.
Nasi ML; Meyers M; Livingston PO; Houghton AN; Chapman PB
Melanoma Res; 1997 Aug; 7 Suppl 2():S155-62. PubMed ID: 9578432
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
8. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
10. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
11. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.
Chapman PB; Lonberg M; Houghton AN
Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
Choi BS; Sondel PM; Hank JA; Schalch H; Gan J; King DM; Kendra K; Mahvi D; Lee LY; Kim K; Albertini MR
Cancer Immunol Immunother; 2006 Jul; 55(7):761-74. PubMed ID: 16187086
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
15. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
Kirkwood JM; Mascari RA; Edington HD; Rabkin MS; Day RS; Whiteside TL; Vlock DR; Shipe-Spotloe JM
Cancer; 2000 Jun; 88(12):2693-702. PubMed ID: 10870051
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
17. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
[TBL] [Abstract][Full Text] [Related]
18. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
19. Bolus high dose interleukin-2 for the treatment of malignant melanoma.
Pappo I; Lotem M; Klein M; Orda R
Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma.
Legha SS; Gianan MA; Plager C; Eton OE; Papadopoulous NE
Cancer; 1996 Jan; 77(1):89-96. PubMed ID: 8630945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
